These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

599 related articles for article (PubMed ID: 33301613)

  • 21. Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT.
    Risitano AM; Marotta S; Ricci P; Marano L; Frieri C; Cacace F; Sica M; Kulasekararaj A; Calado RT; Scheinberg P; Notaro R; Peffault de Latour R
    Front Immunol; 2019; 10():1157. PubMed ID: 31258525
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dosing Patterns of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Ravulizumab in the United States: A Retrospective Claims-Based Analysis.
    Cheng WY; Fishman J; Yenikomshian M; Mahendran M; Kunzweiler C; Vu JD; Duh MS
    Adv Ther; 2024 Jan; 41(1):413-430. PubMed ID: 37999832
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria.
    Schrezenmeier H; Kulasekararaj A; Mitchell L; de Latour RP; Devos T; Okamoto S; Wells R; Popoff E; Cheung A; Wang A; Tomazos I; Patel Y; Lee JW
    Ann Hematol; 2024 Jan; 103(1):5-15. PubMed ID: 37804344
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison.
    Wong R; Fishman J; Wilson K; Yeh M; Al-Adhami M; Zion A; Yee CW; Huynh L; Duh MS
    Adv Ther; 2023 Apr; 40(4):1571-1589. PubMed ID: 36750531
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies.
    Röth A; Rottinghaus ST; Hill A; Bachman ES; Kim JS; Schrezenmeier H; Terriou L; Urbano-Ispizua Á; Wells RA; Jang JH; Kulasekararaj AG; Szer J; Aguzzi R; Damokosh AI; Shafner L; Lee JW
    Blood Adv; 2018 Sep; 2(17):2176-2185. PubMed ID: 30171081
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Resolution of extravascular hemolysis with oral iptacopan monotherapy in a patient with treatment experienced paroxysmal nocturnal hemoglobinuria (PNH).
    Füreder W; Thalhammer R; Valent P
    Wien Klin Wochenschr; 2024 Aug; 136(15-16):472-475. PubMed ID: 38954058
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improvements in hematologic markers and decreases in fatigue with pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and mild or moderate anemia (hemoglobin ≥10 g/dL) who had received eculizumab or were naive to complement inhibitors.
    Panse J; Daguindau N; Okuyama S; Peffault de Latour R; Schafhausen P; Straetmans N; Al-Adhami M; Persson E; Wong RSM
    PLoS One; 2024; 19(7):e0306407. PubMed ID: 39079163
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-Utility Analysis of Ravulizumab Compared with Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria.
    O'Connell T; Buessing M; Johnson S; Tu L; Thomas SK; Tomazos I
    Pharmacoeconomics; 2020 Sep; 38(9):981-994. PubMed ID: 32519233
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab.
    Kulasekararaj AG; Risitano AM; Maciejewski JP; Notaro R; Browett P; Lee JW; Huang M; Geffner M; Brodsky RA
    Blood; 2021 Nov; 138(20):1928-1938. PubMed ID: 34314483
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interim analysis of post-marketing surveillance of ravulizumab for paroxysmal nocturnal hemoglobinuria in Japan.
    Usuki K; Ikezoe T; Ishiyama K; Kanda Y; Gotoh A; Hayashi H; Shimono A; Kitajima A; Obara N; Nishimura JI
    Int J Hematol; 2023 Sep; 118(3):311-322. PubMed ID: 37477863
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.
    Hillmen P; Young NS; Schubert J; Brodsky RA; Socié G; Muus P; Röth A; Szer J; Elebute MO; Nakamura R; Browne P; Risitano AM; Hill A; Schrezenmeier H; Fu CL; Maciejewski J; Rollins SA; Mojcik CF; Rother RP; Luzzatto L
    N Engl J Med; 2006 Sep; 355(12):1233-43. PubMed ID: 16990386
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial.
    Lee JW; Griffin M; Kim JS; Lee Lee LW; Piatek C; Nishimura JI; Carrillo Infante C; Jain D; Liu P; Filippov G; Sicre de Fontbrune F; Risitano A; Kulasekararaj AG;
    Lancet Haematol; 2023 Dec; 10(12):e955-e965. PubMed ID: 38030318
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of human antihuman antibodies to eculizumab after long-term treatment in patients with paroxysmal nocturnal hemoglobinuria.
    Hillmen P; Muus P; Szer J; Hill A; Höchsmann B; Kulasekararaj A; Risitano AM; Van Den Neste E; Liljeholm M; Ebrahim KS; Bedrosian CL; Gao X; Ames D; Socié G
    Am J Hematol; 2016 Mar; 91(3):E16-7. PubMed ID: 26690023
    [No Abstract]   [Full Text] [Related]  

  • 34. Pharmacological and clinical profile of ravulizumab 100 mg/mL formulation for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
    Ariceta G
    Expert Rev Clin Pharmacol; 2023 May; 16(5):401-410. PubMed ID: 37128905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment.
    Subías Hidalgo M; Martin Merinero H; López A; Anter J; García SP; Ataúlfo Gonzalez-Fernández F; Forés R; Lopez-Trascasa M; Villegas A; Ojeda E; Rodríguez de Córdoba S
    Immunobiology; 2017 Feb; 222(2):363-371. PubMed ID: 27644115
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pegcetacoplan: A Review in Paroxysmal Nocturnal Haemoglobinuria.
    Heo YA
    Drugs; 2022 Dec; 82(18):1727-1735. PubMed ID: 36459381
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial.
    de Latour RP; Szer J; Weitz IC; Röth A; Höchsmann B; Panse J; Usuki K; Griffin M; Kiladjian JJ; de Castro CM; Nishimori H; Ajayi T; Al-Adhami M; Deschatelets P; Francois C; Grossi F; Risitano AM; Hillmen P
    Lancet Haematol; 2022 Sep; 9(9):e648-e659. PubMed ID: 36055332
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Eculizumab for Paroxysmal Nocturnal Hemoglobinuria: A Systematic Review and Meta-Analysis.
    Zhou S; Dong X; Chen C; Ma L; Wu Y; Zhou Y; Cui Y
    J Pediatr Hematol Oncol; 2021 Aug; 43(6):203-210. PubMed ID: 33902068
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Norm-based comparison of the quality-of-life impact of ravulizumab and eculizumab in paroxysmal nocturnal hemoglobinuria.
    Schwartz CE; Stark RB; Borowiec K; Nolte S; Myren KJ
    Orphanet J Rare Dis; 2021 Sep; 16(1):389. PubMed ID: 34526067
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial.
    Risitano AM; Röth A; Soret J; Frieri C; de Fontbrune FS; Marano L; Alashkar F; Benajiba L; Marotta S; Rozenberg I; Milojevic J; End P; Nidamarthy PK; Junge G; Peffault de Latour R
    Lancet Haematol; 2021 May; 8(5):e344-e354. PubMed ID: 33765419
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.